WHO Approves Roche’s Actemra/RoActemra Covid 19 Treatment

The World Health Organization has agreed that if Roche’s Actemra/RoActemra Covid 19 therapy complies with their requirements, individuals over the age of 18 may use it to treat serious cases where they are receiving systemic corticosteroids and need extra oxygen or ventilation.

Over one million patients have had Actemra/RoActemra during the pandemic period.

CEO of Roche, Bill Anderson, explained that the company has “partnered with WHO and others throughout the last year to ensure that our Covid 19 medicines and tests can potentially reach more than 100 low-and middle-income countries.”

Two alternative treatments created by Regeneron (Actemra/RoActemra and Ronapreve) were approved and mentioned in ‘WHO’s Therapeutics and Covid 19 Living Guideline’ last year.

Roche distributes their product to multiple organisations working in the Access to Covid 19 Tools Accelerator (ACT-A) program to enable low- and middle-income nations to get hold of treatments. In partnership with Regeneron, the company also interacts with ACT-A partners and UNICEF by distributing Ronapreve to highly vulnerable populations from new variants.

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.